BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 7684949)

  • 1. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
    Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
    Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
    Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.
    Gleave M; Hsieh JT; Gao CA; von Eschenbach AC; Chung LW
    Cancer Res; 1991 Jul; 51(14):3753-61. PubMed ID: 1712249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
    J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.
    Iwasa Y; Mizokami A; Miwa S; Koshida K; Namiki M
    Int J Urol; 2007 Mar; 14(3):233-9. PubMed ID: 17430262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
    Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells.
    Wang LG; Liu XM; Kreis W; Budman DR
    Cancer Res; 1997 Feb; 57(4):714-9. PubMed ID: 9044850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP.
    Henttu P; Vihko P
    Cancer Res; 1993 Mar; 53(5):1051-8. PubMed ID: 7679946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
    Jia L; Coetzee GA
    Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
    Sadar MD; Gleave ME
    Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
    Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
    Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression.
    Peternac D; Klima I; Cecchini MG; Schwaninger R; Studer UE; Thalmann GN
    Prostate; 2008 Sep; 68(12):1307-18. PubMed ID: 18512728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
    Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human prostate cancer progression models and therapeutic intervention.
    Chung LW; Kao C; Sikes RA; Zhau HE
    Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
    Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
    J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rap2 regulates androgen sensitivity in human prostate cancer cells.
    Bigler D; Gioeli D; Conaway MR; Weber MJ; Theodorescu D
    Prostate; 2007 Oct; 67(14):1590-9. PubMed ID: 17918750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The atypical GATA protein TRPS1 represses androgen-induced prostate-specific antigen expression in LNCaP prostate cancer cells.
    van den Bemd GJ; Jhamai M; Brinkmann AO; Chang GT
    Biochem Biophys Res Commun; 2003 Dec; 312(3):578-84. PubMed ID: 14680804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of prostate-specific antigen expression by the junctional adhesion molecule A.
    Wang Q; Zheng JY; Kreth J; Yan X; Kamata M; Campbell RA; Xie Y; Chiu R; Berenson JR; Shi W; Chen IS; Pang S
    Urology; 2009 May; 73(5):1119-25. PubMed ID: 18602143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.